ICPT Share Price

Open 113.00 Change Price %
High 114.40 1 Day 1.45 1.29
Low 112.20 1 Week -5.87 -4.91
Close 113.72 1 Month 5.83 5.40
Volume 356242 1 Year -24.88 -17.95
52 Week High 177.93
52 Week Low 96.63
ICPT Important Levels
Resistance 2 115.76
Resistance 1 114.92
Pivot 113.44
Support 1 112.52
Support 2 111.68
NASDAQ USA Most Active Stocks
GOOG 941.86 0.84%
GOOG 941.86 0.84%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DCTH 0.03 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
MNGA 1.92 966.67%
HAUP 0.17 88.89%
NUTR 42.15 50.54%
LOCM 0.09 50.00%
OPXAW 0.03 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
COOL 16.78 24.85%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

ICPT Technical Analysis 3
As on 22nd May 2017 ICPT Share Price closed @ 113.72 and we RECOMMEND Sell for LONG-TERM with Stoploss of 129.06 & Sell for SHORT-TERM with Stoploss of 115.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
ICPT Target for May
1st Target up-side 118.52
2nd Target up-side 122.85
3rd Target up-side 127.18
1st Target down-side 106.18
2nd Target down-side 101.85
3rd Target down-side 97.52
ICPT Other Details
Segment EQ
Market Capital 330403136.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.interceptpharma.com
ICPT Address
ICPT
450 West 15th Street
New York, NY 10011
United States
Phone: 646-747-1000
Fax: 646-747-1001
ICPT Latest News
Interactive Technical Analysis Chart Intercept Pharmaceuticals, Inc. ( ICPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Intercept Pharmaceuticals, Inc.
ICPT Business Profile
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.